COMPASS Pathways appoints Kabir Nath as Chief Executive Officer
19 juil. 2022 08h00 HE
|
COMPASS Pathways
Kabir Nath will build upon COMPASS’ success and lead the development of novel models of care to accelerate patient access to evidence-based innovation in mental health care George Goldsmith remains...
COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting
23 mai 2022 07h00 HE
|
COMPASS Pathways
Positive data from phase IIb study shows potential of COMP360 psilocybin therapy in treatment-resistant depression London, UK – 23 May 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a...
COMPASS Pathways to participate in upcoming Citi’s Biopharma Virtual Co-Panel Day and H.C. Wainwright Global Investment Conference
12 mai 2022 08h00 HE
|
COMPASS Pathways
LONDON, May 12, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways plc announces first quarter 2022 financial results and business highlights
10 mai 2022 07h00 HE
|
COMPASS Pathways
LONDON, May 10, 2022 (GLOBE NEWSWIRE) -- Highlights: End of phase II meeting held with FDAAward of Innovation Passport as part of the UK MHRA Innovative Licensing and Access...
COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults
09 mai 2022 07h00 HE
|
COMPASS Pathways
London, UK – 9 May 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today...
COMPASS Pathways plc to announce first quarter 2022 financial results on 10 May 2022
03 mai 2022 08h00 HE
|
COMPASS Pathways
LONDON, May 03, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression
03 mai 2022 07h00 HE
|
COMPASS Pathways
Positive early signals seen in two investigator-initiated studies presented at the Society of Biological Psychiatry Annual Meeting in New Orleans London, UK – 3 May 2022 COMPASS...
COMPASS Pathways partners with One Mind to fund Rising Star Awards for the next generation of mental health researchers
20 avr. 2022 07h00 HE
|
COMPASS Pathways
London, UK – 20 April 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways to participate in Needham Healthcare conference
04 avr. 2022 08h00 HE
|
COMPASS Pathways
LONDON, April 04, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways and partners launch The Centre for Mental Health Research and Innovation, in the UK
24 mars 2022 05h00 HE
|
COMPASS Pathways
Pioneering collaboration with King’s College London and South London and Maudsley NHS Foundation Trust London, UK, 24 March 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”),...